Trials / Conditions / MYD88 Gene Mutation
MYD88 Gene Mutation
3 registered clinical trials studyying MYD88 Gene Mutation.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Completed | Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL NCT05233033 | Kymera Therapeutics, Inc. | Phase 1 |
| Unknown | Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBC NCT04994626 | Chinese Academy of Medical Sciences | Phase 2 |
| Active Not Recruiting | Ibrutinib + Venetoclax in Untreated WM NCT04273139 | Dana-Farber Cancer Institute | Phase 2 |